Year: 2025

Did you know your eye injection drugs need to stay cold? A new study found 100% of patients let their anti-VEGF medicine get too warm at home—some for over 48 hours! No eye problems happened this time, but it’s a big hint to keep that fridge handy.

RESTORE study: Lenadogene nolparvovec boosts vision in LHON for 5 years—both eyes improve with one shot!

BLINK2 shows multifocal contact lenses keep myopia in check even after kids stop wearing them—small changes, big hope!

Tiny microdrops outshine standard drops in ROP screening—equal dilation, fewer risks. A preterm game-changer?

Macular hole repair in Alport syndrome reveals a clingy vitreous and missing ILM—can peeling the hyaloid alone save the day? This case says yes!

A simple blood test—plasma ctDNA—cracked the case of mysterious choroidal metastases, revealing lung cancer and guiding swift treatment. Could this be the future of ocular oncology?

A new study in the American Journal of Ophthalmology pits OCT B-scans against en face imaging to spot early macular atrophy in AMD. The verdict? En face imaging catches what B-scans miss, offering a faster, sharper way to track progression. Dive into the details of this retina research breakthrough!

A recent study suggested a link between glucagon-like peptide 1 (GLP-1) receptor agonists and a slight decrease in intraocular pressure (IOP). However, a new analysis points out potential oversights in the research methodology that may affect the reliability of these findings. Key concerns include the absence of propensity score matching, inadequate consideration of metformin co-usage, and failure to account for known glaucoma risk factors like corticosteroid use. These factors could lead to inaccurate conclusions about the true impact of GLP-1 receptor agonists on IOP.

In this 12-month, multicenter randomized controlled trial, children with high myopia received either repeated low-level red-light (RLRL) therapy with single vision spectacles or single vision spectacles alone. The RLRL group demonstrated significant axial length shortening, a reduction in myopic progression, and increases in choroidal and retinal thickness, indicating that RLRL therapy is a safe and effective method for inhibiting myopia progression in children with high myopia.